A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Bumex, Burinex 
Synonyms :
bumetanide 
Class :
Diuretics, Loop 
Brand Name :
Bumex, Burinex 
Synonyms :
bumetanide 
Class :
Diuretics, Loop 
Dosage Forms & Strengths 
Injectable solution 
0.25mg/mL
Tablet
0.5mg
1mg
2mg
0.5 - 2
mg
Orally 
once a day
; may be repeated every 4-5 hours for up to 2 doses; maximum daily dose is 10 mg
IM- 0.5-1 mg intramuscular once; may be repeated every 2-3 hours for up to 2 doses; maximum daily dose is 10 mg.
IV- 1 mg intravenous at first, then 0.5-2 mg/hr
off-label:
1
mg
Intravenous (IV)
loading dose, followed by 0.5-2 mg/day oral divided every 12 hours.
Safety and efficacy not established.
Refer to adult dosing.
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
may decrease the diuretic effect of loop diuretics
may decrease the diuretic effect of nonsteroidal anti-inflammatory agents
may have an increased risk of rhabdomyolysis & myoglobinuria when combined with bumetanide
arsenic trioxide: they may enhance the hypotensive effect of loop diuretics
may decrease the diuretic effect when combined with loop diuretics
may increase the hypotensive effect
opioid agonists increase the toxicity of diuretics
opioid agonists increase the toxicity of diuretics
amikacin liposome (oral inhalation)Â
they decrease the nephrotoxicity of liposomal amikacin oral inhalation
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
The administration of Loop Diuretics may intensify the hyponatremic impact of desmopressin
The use of Loop diuretics may increase the QTc-prolonging influence of promazine
may diminish the effects of indomethacin by pharmacodynamic antagonism
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may increase the risk of adverse effect of cardiac glycosides
may increase the risk of adverse effect of cardiac glycosides
may increase the risk of adverse effect of cardiac glycosides
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
It may enhance the effects when combined with maitake by pharmacodynamic synergism
They may diminish the absorption when combined with bile acid sequestrants
It may enhance toxicity when combined with beclomethasone, inhaled by enhancing elimination
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
may have an increased adverse/toxic effect when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may have an increased adverse/toxic effect when combined with aminoglycosides
When loracarbef is used together with bumetanide, the risk or seriousness of nephrotoxicity is enhanced
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
When cefmenoxime is used together with bumetanide, this leads to enhanced risk or seriousness of nephrotoxicity
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
bumetanide: it may increase the risk of adverse effects with phentolamine
bumetanide may increase the excretion rate of almasilate, potentially lowering serum levels and reducing efficacy
bumetanide: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
loop Diuretics may increase the hypokalemic effect of dichlorphenamide
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
loop Diuretics may enhance the hypokalemic effect of topiramate
may decrease the serum potassium levels
insulin degludec/insulin aspartÂ
may decrease the effect of each other
empagliflozin increases the effect of hypotension of loop diuretics
may increase the hypokalemic effect of corticosteroids
loop diuretics may increase the risk of adverse effect of allopurinol
may reduce the rate of absorption of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may increase the hypotensive effect of calcium channel blockers
hydrochlorothiazide/aliskirenÂ
may increase the hypotensive effect of antihypertensive agents
may increase the hypotensive effect of angiotensin receptor II blockers
may increase the hypokalemic effect of beta2 agonists
may increase the hypokalemic effect of beta2 agonists
may diminish the therapeutic effect of salicylates
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may increase the hypokalemic effect when combined
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the hypokalemic effect of Beta2-Agonists
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
The effectiveness of loop diuretics could be reduced by the presence of probenecid
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
canagliflozin: they may increase the hypotensive effect of loop diuretics
guanethidine: they may increase the hypotensive effect of loop diuretics
Loop Diuretics have the potential to increase the toxic or harmful impact of levosulpiride
loop diuretics may increase the nephrotoxic effect of cefotiam
The QTc-prolonging effect of bilastine may be enhanced by the concurrent use of loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
neomycin/polymyxin B/bacitracin topical
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
choline magnesium trisalicylate
may decrease the diuretic effect of loop diuretics
nephrotoxicity associated with cisplatin may be enhanced with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
combining bumetanide with carbimazole may increase the risk or severity of myoglobinuria, myopathy, or rhabdomyolysis
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the adverse/toxic effect of cardiac glycosides
may increase the adverse/toxic effect of cardiac glycosides
may increase the adverse/toxic effect of cardiac glycosides
glycopyrrolate inhaled and formoterolÂ
may enhance the effects of the other by pharmacodynamic synergism
loop diuretics have the potential to amplify the QTc-prolonging effect of dofetilide
The serum concentration of foscarnet can be enhanced by the concurrent use of loop diuretics
Actions and spectrum: 
bumetanide is a medication that belongs to a class of drugs known as loop diuretics. It primarily treats heart failure, Edema (swelling), and high blood pressure.
The mechanism of action of bumetanide is to inhibit the reabsorption of Na and Cl ions in the renal tubules, resulting in increased excretion of these ions from the body. This causes an increase in urine volume and a decrease in blood volume, which can reduce fluid accumulation and Edema.
Frequency defined  
1-10% 
Hyperglycemia (7%)
Variations in phosphorus (5%)
Increased serum creatinine (7%)
Variations in CO2 content (4%)
Hyponatremia (9%)
Variations in calcium (2%)
Variations in bicarbonate (3%)
Dizziness (1%)
Ototoxicity (1%)
Muscle cramps (1%)
>10% 
Hyperuricemia (18%)
Hypochloremia (15%)
Hypokalemia (15%)
Azotemia (11%)
<1% 
Asterixis
Dehydration
Hypotension
Orthostatic hypotension
Pruritus
Rash
Renal failure
Severe skin reactions
Vertigo
Vomiting
Black box warning: 
when used in high doses, can cause severe diuresis and electrolyte depletion.
Contraindications/caution: 
Contraindications 
Cautions 
Pregnancy consideration: 
US FDA Pregnancy category: C
Lactation- Safety and efficacy not established
Pregnancy category 
Category A- Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B- There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C- Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D- There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X- Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N- There is no data available for the drug under this category.
Pharmacology: 
bumetanide inhibits sodium and chloride’s reabsorption in Henle’s ascending loop, thereby causing the excretion of water and sodium, chloride, calcium, magnesium, potassium, and hydrogen ions.
Pharmacodynamics: 
bumetanide works by blocking the action of the hormone aldosterone in the renal tubules of the kidney. Aldosterone regulates the balance of salt and water in the body, and blocking its action leads to increased excretion of salt and water in the urine.
Pharmacokinetics: 
Absorption 
bumetanide is rapidly and well absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. The absorption of bumetanide is not significantly affected by food.
Distribution 
bumetanide is highly bound to plasma proteins, which limits its distribution throughout the body. The volume of distribution of bumetanide is small, indicating that it is primarily concentrated in the renal tubules.
Metabolism 
bumetanide is not metabolized significantly and is primarily excreted unchanged in the urine.
Elimination and excretion 
The half-life of bumetanide is 1 to 2 hours, and the drug is rapidly excreted in the urine. The elimination of bumetanide from the body is primarily by renal excretion, with less than 5% oral dose is excreted in the faeces.
Administration: 
Oral administration
The primary route of administration for bumetanide is oral. It is taken by mouth as a tablet or oral solution. The starting dose for adults is usually 1 to 2 milligrams, taken once or twice daily. The maximum daily dose is 10 milligrams.
Patient information leaflet 
Generic Name- bumetanide
Pronounced- byoo-me-tuh-nide
Why do we use bumetanide? 
bumetanide is used to treat several conditions like-
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
